EyePoint, Inc.
EYPTEyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases.
Earnings
Next report
Aug 5, 2026 (In 1 week)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases. The company leverages its proprietary Durasert drug delivery technology to provide sustained-release, intraocular treatments that reduce the frequent injection burden associated with standard-of-care therapies. Its lead pipeline candidates target major ocular conditions including wet age-related macular degeneration and diabetic macular edema.
A specialized player in the ophthalmic drug delivery space, utilizing a proven sustained-release technology platform to differentiate from standard-of-care biologics.
Questions, answered.
- What is EyePoint, Inc. 's market cap?
- EyePoint, Inc. (EYPT) has a market capitalization of $1.0B and trades on NASDAQ.
- What is EyePoint, Inc. 's revenue and profitability?
- EyePoint, Inc. generated $7.6M in trailing twelve-month revenue with a net loss of $271.6M, representing a net margin of -3566.6%, with free cash flow of -$271.5M. These figures are based on the Q1 2026 filing.
- Who are EyePoint, Inc. 's competitors?
- EyePoint, Inc. 's key competitors include 4D Molecular Therapeutics, Regeneron Pharmaceuticals, Inc., Kodiak Sciences, Inc., and others. These companies compete in similar markets and product categories.
- Who does EyePoint, Inc. partner with?
- EyePoint, Inc. 's notable partners include Equinox Science, LLC, Betta Pharmaceuticals Co., Ltd., ANI Pharmaceuticals, Inc., and others.
- Where is EyePoint, Inc. headquartered?
- EyePoint, Inc. is headquartered in United States of America and employs approximately 144 people. It has been publicly traded since 2005.
